CN102066557A - 加速离体产生调节性t细胞的方法和组合物 - Google Patents

加速离体产生调节性t细胞的方法和组合物 Download PDF

Info

Publication number
CN102066557A
CN102066557A CN2009801230830A CN200980123083A CN102066557A CN 102066557 A CN102066557 A CN 102066557A CN 2009801230830 A CN2009801230830 A CN 2009801230830A CN 200980123083 A CN200980123083 A CN 200980123083A CN 102066557 A CN102066557 A CN 102066557A
Authority
CN
China
Prior art keywords
cells
regulatory
composition
tgf
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801230830A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·霍尔维奇
J·D·格雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of CN102066557A publication Critical patent/CN102066557A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2009801230830A 2008-04-11 2009-04-10 加速离体产生调节性t细胞的方法和组合物 Pending CN102066557A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4430608P 2008-04-11 2008-04-11
US61/044306 2008-04-11
PCT/US2009/040190 WO2009126877A2 (en) 2008-04-11 2009-04-10 Methods and compositions for accelerating the generation of regulatory tcells ex vivo

Publications (1)

Publication Number Publication Date
CN102066557A true CN102066557A (zh) 2011-05-18

Family

ID=40853828

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801230830A Pending CN102066557A (zh) 2008-04-11 2009-04-10 加速离体产生调节性t细胞的方法和组合物

Country Status (7)

Country Link
US (1) US20090257988A1 (enExample)
EP (1) EP2281031A2 (enExample)
JP (1) JP2011519271A (enExample)
CN (1) CN102066557A (enExample)
AU (1) AU2009234210A1 (enExample)
CA (1) CA2721088A1 (enExample)
WO (1) WO2009126877A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105597090A (zh) * 2014-11-14 2016-05-25 中国科学院上海生命科学研究院 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
CN108060129A (zh) * 2017-12-11 2018-05-22 上海药明生物技术有限公司 调节性t细胞体外扩增方法
CN115768870A (zh) * 2020-06-01 2023-03-07 促进军事医学的亨利·M·杰克逊基金会公司 诱导型调节性t细胞，其生产方法及其用途
CN119592507A (zh) * 2024-12-03 2025-03-11 哈尔滨优莱福生物科技有限公司 一种人外周血调节性t细胞的体外扩增试剂盒及其使用方法和应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228172B2 (en) * 2008-06-19 2016-01-05 The Trustees Of The University Of Pennsylvania Inducible regulatory T-cell generation for hematopoietic transplants
CN102459577B (zh) * 2009-05-18 2014-08-20 特拉科斯有限公司 适合临床应用于免疫介导性疾病的、具有增强型抑制功能的调节性t细胞的体外扩增方法
CN102971416B (zh) * 2010-04-22 2018-03-30 南加州大学 用于扩增和稳定天然调节性t细胞的方法和组合物
CN102321580A (zh) * 2011-08-23 2012-01-18 郑颂国 一种治疗自体自身免疫性疾病的调节t细胞及其制备方法
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
CA2936259A1 (en) * 2014-01-17 2015-07-23 Dbv Technologies Epicutaneous immunorebalancing
US10905706B2 (en) 2015-01-08 2021-02-02 The Johns Hopkins University Compositions and methods to accelerate resolution of acute lung inflammation
EP3362074B1 (en) * 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3368659A1 (en) * 2015-10-28 2018-09-05 Life Technologies AS Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
WO2018106885A1 (en) 2016-12-07 2018-06-14 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
CN114921468A (zh) 2017-01-30 2022-08-19 国立大学法人京都大学 新型化合物以及调节性t细胞的制造方法
WO2019125981A1 (en) * 2017-12-19 2019-06-27 Musc Foundation Of Research Development T regulatory (trey) cell translantation in osteogenesis imperfecta (oi)
US20210238551A1 (en) 2018-08-22 2021-08-05 Osaka University Method for Generating Regulatory T Cells
US20210290742A1 (en) * 2018-09-27 2021-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
GB202008957D0 (en) * 2020-06-12 2020-07-29 Autolus Ltd Culture medium
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
US20100061984A1 (en) * 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
ES2367012T3 (es) * 2006-02-28 2011-10-27 Charite-Universitätsmedizin Berlin Detección y control de calidad de linfocitos t reguladores a través del análisis de metilación del adn del gen foxp3.
EP2167647A2 (en) * 2007-06-13 2010-03-31 La Jolla Institute For Allergy And Immunology Regulatory t cells and methods of making and using same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105597090A (zh) * 2014-11-14 2016-05-25 中国科学院上海生命科学研究院 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
CN108060129A (zh) * 2017-12-11 2018-05-22 上海药明生物技术有限公司 调节性t细胞体外扩增方法
CN115768870A (zh) * 2020-06-01 2023-03-07 促进军事医学的亨利·M·杰克逊基金会公司 诱导型调节性t细胞，其生产方法及其用途
CN119592507A (zh) * 2024-12-03 2025-03-11 哈尔滨优莱福生物科技有限公司 一种人外周血调节性t细胞的体外扩增试剂盒及其使用方法和应用

Also Published As

Publication number Publication date
AU2009234210A2 (en) 2010-12-16
WO2009126877A3 (en) 2009-12-03
CA2721088A1 (en) 2009-10-15
EP2281031A2 (en) 2011-02-09
WO2009126877A2 (en) 2009-10-15
AU2009234210A1 (en) 2009-10-15
US20090257988A1 (en) 2009-10-15
JP2011519271A (ja) 2011-07-07

Similar Documents

Publication Publication Date Title
CN102066557A (zh) 加速离体产生调节性t细胞的方法和组合物
JP7451468B2 (ja) 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用
KR101301923B1 (ko) 인간 혈액 유래의 ｃｄ4＋ｃｄ25＋ 조절성 ｔ 세포
JP7344898B2 (ja) 養子注入されたｔ細胞の持続性を増強する方法
Sakuraba et al. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease
US8053235B2 (en) Methods of generating antigen-specific CD4+CD25+regulatory T cells, compositions and methods of use
ES2686593T3 (es) Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
JP6068432B2 (ja) 治療における調節性ｔ細胞の使用方法
Gregori et al. Isolation, expansion, and characterization of human natural and adaptive regulatory T cells
CN108291203A (zh) Cd8+cd45rc低treg的新亚群及其用途
US20160136204A1 (en) Production and therapeutic uses of th1-like regulatory t cells
US20060286067A1 (en) Methods for making and using regulatory T cells
US20230015932A1 (en) Method of generation of lympho-myeloid niches
US20070128670A1 (en) Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and use thereof
JP2020108405A (ja) 高活性ｎｋ細胞、およびその利用
CN102971416B (zh) 用于扩增和稳定天然调节性t细胞的方法和组合物
CN104721229A (zh) 治疗肠炎性病症的组合物
CN121057812A (zh) 人诱导性调节性t细胞及其制作方法以及用于治疗或预防t细胞相关疾病的药物组合物
Hughes The stage-specific effects of IL-1β on human natural killer cell development

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110518